An Integrative Ayurvedic and Conventional Approach to Clinically Interpreted Ruddhapatha Kamala : A Case Report Section Case Reports

##plugins.themes.academic_pro.article.main##

Vishwajeet Govindrao Mehetre
Savita Arjun Wale

Abstract

Background: Kamala is an Ayurvedic clinical entity characterized by yellowish discoloration of the eyes, urine, and body tissues. Ruddhapatha Kamala is described in the context of obstruction of the normal movement of aggravated Pitta by Kapha and provides a conceptual Ayurvedic correlation for jaundice associated with impaired biliary flow. This case illustrates the application of this Ayurvedic diagnostic assessment alongside contemporary clinical and biochemical assessment.


Case Presentation: A 20-year-old male presented with yellowish discoloration of the eyes and urine, decreased appetite, and leg cramps, with no significant past medical history. Examination revealed icterus and clay-coloured stool. Ultrasonography demonstrated mild hepatosplenomegaly, with a liver span of 15.1 cm and splenic length of 12.8 cm, along with mild pseudothickening of the gallbladder wall. Ultrasonography did not document definite structural biliary obstruction. Initial investigations revealed total serum bilirubin of 10.19 mg/dL (direct 6.48 mg/dL; indirect 3.71 mg/dL), SGOT 311 IU/L, and SGPT 330 IU/L. Urinary bile salts and bile pigments were positive, while HBsAg and HIV were negative. Based on the clinical presentation, Ayurvedic assessment, biochemical findings, and imaging, the condition was interpreted as Ruddhapatha Kamala. The patient received conventional supportive treatment concurrently with Ayurvedic medicines, including Arogyavardhini Vati, Kamdudha Vati, Triphala Churna, Trikatu Churna, Sharpunkha–Amalaki Churna, and Bhumyamalaki Swarasa. By Day 5, total bilirubin decreased to 5.30 mg/dL and SGOT to 67 IU/L, although SGPT was 337 IU/L; urinary bile salts, bile pigments, and urobilinogen were absent. By Day 8, total bilirubin further decreased to 2.94 mg/dL, with marked symptomatic improvement and minimal residual weakness.


Conclusion: This case demonstrates substantial clinical and biochemical improvement during integrative management of a patient interpreted as having Ruddhapatha Kamala. The case highlights the potential utility of integrating Ayurvedic pathophysiological assessment with objective biochemical and imaging parameters.

##plugins.themes.academic_pro.article.details##

Author Biography

Savita Arjun Wale, Assistant Professor,Rognidan Vikritividnyan Department,Vasantdada Patil Ayurvedic Medical College,Sangli (M.S.)

Assistant Professor,Rognidan Vikritividnyan Department,Vasantdada Patil Ayurvedic Medical College,Opposite to Income Tax Office,South Shivajinagar,Sangli,Maharashtra- 416416.

How to Cite
Vishwajeet Govindrao Mehetre, & Savita Arjun Wale. (2026). An Integrative Ayurvedic and Conventional Approach to Clinically Interpreted Ruddhapatha Kamala: : A Case Report. National Journal of Research in Ayurved Science, 14(04). https://doi.org/10.52482/ayurlognjras.v14i04.1375

References

  1. Bonheur JL. Biliary obstruction. Medscape. Available from: Medscape – Biliary Obstruction https://emedicine.medscape.com/article/187001-overview?utm_source retrieved on 7th Sept. 2026.
  2. Anstee QM, Jones DEJ. Liver and biliary tract disease. In: Walker BR, Colledge NR, Ralston SH, Penman ID, editors. Davidson's Principles and Practice of Medicine. 22nd ed. Edinburgh: Elsevier; 2014. p. 928-929.
  3. Agnivesha. Charaka Samhita, revised by Charaka and Dridhabala, with Ayurveda Dipika commentary of Chakrapanidatta. Yadavji Trikamji Acharya, editor. Varanasi: Chaukhamba Orientalia; 2015. Chikitsa Sthana 15/4. p. 526.
  4. Agnivesha. Charaka Samhita, revised by Charaka and Dridhabala, with Ayurveda Dipika commentary of Chakrapanidatta. Yadavji Trikamji Acharya, editor. Varanasi: Chaukhamba Orientalia; 2015. Chikitsa Sthana 15/124. p. 532.
  5. Agnivesha. Charaka Samhita, revised by Charaka and Dridhabala, with Ayurveda Dipika commentary of Chakrapanidatta. Yadavji Trikamji Acharya, editor. Varanasi: Chaukhamba Orientalia; 2015. Chikitsa Sthana 15/4. p. 526.
  6. Agnivesha. Charaka Samhita, revised by Charaka and Dridhabala, with Ayurveda Dipika commentary of Chakrapanidatta. Yadavji Trikamji Acharya, editor. Varanasi: Chaukhamba Orientalia; 2015. Chikitsa Sthana 15/124. p. 532.
  7. U.S. Food and Drug Administration. Clinical pharmacology review: pantoprazole sodium. Silver Spring (MD): FDA; 2010. FDA pantoprazole clinical pharmacology review https://www.fda.gov/media/116701/download?utm_source retrieved on 7th Sept. 2026.
  8. DailyMed. Ceftriaxone for injection, USP: prescribing information. Bethesda (MD): National Library of Medicine; 2022. Ceftriaxone prescribing information https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5cd2d96f-83e5-4326-ae87-d0ede4ba493a&utm_source retrieved on 7th Sept. 2026.
  9. Dange SV, Patki PS, Bapat VM, Shrotri DS. Effect of 'Arogyavardhini' against carbon tetrachloride-induced hepatic damage in albino rats. Indian J Physiol Pharmacol. 1987;31(1):25-9.
  10. Kanase R, Patil S, Kanase A. Effect of hepatoprotective Ayurvedic drugs on lysosomal enzymes during hepatic injury induced by single dose of CCl4. Indian J Exp Biol. 1994;32(5):328-32.
  11. Sharma R, Jadhav M, Choudhary N, Kumar A, Rauf A, Gundamaraju R, et al. Deciphering the impact and mechanism of Trikatu, a spices-based formulation on alcoholic liver disease employing network pharmacology analysis and in vivo validation. Front Nutr. 2022;9:1063118.
  12. Sowjanya K, Girish C, Bammigatti C, Prasanna Lakshmi NC. Efficacy of Phyllanthus niruri on improving liver functions in patients with alcoholic hepatitis: a double-blind randomized controlled trial. Indian J Pharmacol. 2021;53(6):474-80.
  13. Peterson CT, Denniston K, Chopra D. Therapeutic uses of Triphala in Ayurvedic medicine. J Altern Complement Med. 2017;23(8):607-14.